The online-only Data Supplement is available with this article at http://stroke.ahajournals.org/lookup/suppl
T he informed consent process is a major limiting step for enrollment in clinical investigations involving patients with acute ischemic stroke because of the frequent impairment of language, judgment, and mental status. 1 Considering the FDA's premise that the physical signature of a legally authorized representative (LAR) is necessary for trial enrollment, the consenting process in time-sensitive stroke studies becomes challenging. Thrombectomy is typically performed in comprehensive stroke centers, and a sizeable portion of large vessel occlusion strokes originates via transfer. Unfortunately, the distances and traffic from referring hospitals constitute major obstacles; therefore, a form of remote consenting is urgently needed.
Modern technology provides unprecedented opportunities. Although the Food and Drug Administration has published guidelines for the use of electronic media for clinical investigations, the use of electronic consenting has never been reported in the setting of research involving acute ischemic stroke. We aim to describe the first experience with electronic informed consenting (e-Consent) in trials of cerebral thrombectomy for patients with acute ischemic stroke.
Methods
This was a retrospective analysis of prospectively collected data with the use of e-Consent in thrombectomy trials in our institution. It was piloted in the DAWN trial (Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention With Trevo). This trial randomized patients with large vessel occlusion strokes presenting within 6 to 24 hours of last seen normal to either stent-retriever thrombectomy or best medical therapy. Subsequently, e-Consent was used in the ARISE-II (Analysis of Revascularization in Ischemic Stroke With EmboTrap) trial, a single-arm trial that evaluated the use of a novel thrombectomy device in patients presenting within 8 hours of last known normal.
Background and Purpose-The informed consent process is a major limitation for enrollment in acute stroke clinical investigations. We aim to describe the novel application of smartphone electronic informed consenting (e-Consent) in trials of cerebral thrombectomy. The DAWN trial enrollment at our institution began in January 2015. e-Consent was institutional review board approved in December 2016, and trial enrollment ended in February 2017. The ARISE-II trial study period comprised August 2016 to February 2017 (e-Consent was approved on the last day of the trial's enrollment period).
Methods-The
After evaluation of inclusion/exclusion criteria, investigators sought out the appropriate LAR. If the patient presented to the emergency department or was transferred with a LAR present, a face-to-face discussion would take place. In patients without any accompanying family, attempts of reaching a LAR would occur (typically intermediated by the outside hospital staff providing contact numbers). Before e-Consent, transfers from outside hospitals involved difficult remote consenting practices. When an eligible patient for a research study was identified before transfer, and a LAR was present at the outside hospital, attempts to fax the consent forms would be performed if referring hospital personnel were available to facilitate. In case of failure, family members were told to drive toward our center (even before the patient departed the referring hospital).
Recognizing that this practice was inefficient, the authors developed a novel e-Consent tool. REDCap (Research Electronic Data Capture; Vanderbilt University, TN) is a secure, Health Insurance Portability and Accountability Act compliant, web-based platform designed for research data capture. Data were collected and managed using the REDCap tools hosted at Emory University, deemed to provide an intuitive interface for validated data entry. 2 An institutional review board application was approved. REDCap was used to create a survey project located on a static URL that can be remotely accessed (via smartphone or computer web browser).
As soon as the LAR was reached, a discussion on the trial was performed by one physician/investigator via phone. Regardless of the geographical position of the LAR, a standard link to the URL is sent via text message and/or email to the LAR, generating a primary instrument (e-Consent form). Figure 1 depicts the e-Consent appearance on the LAR's smartphone screen. The required actions include entering the LAR's email address (for a copy of the consent) and names of the patient and LAR, selecting relationship status, and signing freehand. A record/record ID are automatically created in the database and an e-Consent Process Attestation form autogenerated, which is later completed by the physician who obtained the consent (Figure 2) .
Statistical Analysis
Transferred patients were categorized into conventional consenting (defined as paper-based consenting in person or via fax) and e-Consent. Continuous variables were reported as mean±SD. Categorical variables were reported as proportions. Between group comparisons for continuous/ordinal variables were made with Student t test/ Mann-Whitney U. Statistical analyses were performed using SPSS Statistics 22 (IBM-Armonk, NY).
Results
Of 273 thrombectomies performed within the DAWN study period, 47 patients were consented and 38 (81%) were enrolled in the DAWN trial after 9 (19%) screen failures. Figure 3 demonstrates the consent rate within the study period, with relatively steady enrollment rates for 18 months followed by an increment after e-Consent was approved. Of the enrolled patients, 29 (76%) were transferred from outside hospitals.
A total of 6 surrogates were approached and e-Consented (Figure in the online-only Data Supplement) in the DAWN trial. All of the approached LAR (or accompanying family members) did have a smartphone available. None of the e-Consented surrogates had any reservations about the method used for consenting. Of the e-Consents, 4 were enrolled in the trial while 2 patients were screen failures (excluded because of low National Institutes of Health Stroke Scale or large core, respectively). The enrolled e-Consented patients (n=4) had 
002).
A total of 14 patients were enrolled in the ARISE-II trial. e-Consenting was approved in the last day of open trial enrollment. One patient was e-Consented, being a screen failure.
Discussion
Our pilot study demonstrates that e-Consenting is feasible and may lead to enhanced rates of enrollment and reduced times to randomization in time-sensitive acute stroke clinical trials.
Trial enrollment in acute stroke is challenging, and the consenting process constitutes a major barrier. Considering the cognitive, language, motor/coordination, and visual deficits typically seen in acute stroke, the inability to provide informed consent is common. 1 Surrogate informed consent was used to enroll 70% of patients in the pivotal NINDS rt-pa trial (The National Institute of Neurological Disorders and Stroke Thrombolysis Trial). 3 Because of the higher stroke severity in large vessel occlusion strokes, surrogate consenting is expected to became more common in thrombectomy. Therefore, optimization of the surrogate informed consent process represents a critical step to enhance the opportunity of trial participation.
Modern technology provides novel opportunities. Worldwide, mobile device subscriptions nearly match the global population, and the number of smartphone users in 2015 approached 3 billion. 4, 5 As such, e-Consent represents an attractive option. The Food and Drug Administration has recently released recommendations on the use of electronic media and processes to obtain informed consent for Food and Drug Administration-regulated investigations: the use of an electronic signature (encrypted digital signature, electronic signature pad, voice print, digital fingerprint) is permitted; subjects/surrogates should receive a copy of their e-Consent; the computer system that supports the e-Consent must be secure, with restricted access, and be Health Insurance Portability and Accountability Act compliant. In addition, the e-Consent must be reviewed and approved by the local institutional review board. 6 The main difficulty encountered by our group was to identify a Health Insurance Portability and Accountability Act compliant method because multiple vendors were not considered appropriate by the local institutional review board.
Despite its multiple pragmatic advantages, e-Consent also has particular drawbacks. The development of an e-Consent platform can be expensive, especially if graphic elements are used to enhance comprehension; however, the reutilization of templates may attenuate costs. 7 The technical requirements and costs related to production and maintenance of the reported electronic system were minimal. The system used in the current report allowed straightforward modifications in the layout and text. An important concern of web-based applications relates to data security and privacy. 7, 8 Fortunately, the presented method can use smartphones' web browsers, which use data encryption and, increasingly, biometric identification. Although the verification of identity of the surrogate may be another potential limitation, the authentication may be increasingly secure with potential upload of state-issued identification, personal questions, digital signature, username and passwords, and biometric approaches. 6 Future investigation of the e-Consent practice involving stroke patient/surrogate feedback is warranted.
Conclusions
e-Consenting has streamlined the consenting process in a randomized clinical trial involving patients with emergent large vessel occlusion strokes. e-Consent may enhance enrollment rates and optimize time to randomization in thrombectomy and acute stroke trials. Future studies are warranted. 
